Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes
Yıl: 2022 Cilt: 18 Sayı: 4 Sayfa Aralığı: 353 - 359 Metin Dili: İngilizce DOI: 10.4274/ejbh.galenos.2022.2022-8-1 İndeks Tarihi: 10-10-2022
Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes
Öz: Objective: A few studies suggest that mucinous breast carcinoma (MBC) is a rare breast carcinoma with good prognostic features. Therefore, the aim of this study was to evaluate biological features and clinicopathological characteristics of pure mucinous breast carcinoma (PMBC) to determine clinical outcome in PMBC. Materials and Methods: The data of 87 patients diagnosed with PMBC between November 2004 and February 2022 were retrospectively analyzed in terms of clinicopathological and demographic characteristics, management, and outcome. Results: The majority of the patients in this study were female, with a median (range) age of 63 (28–90) years. Out of 87 patients, 60 had breast conserving surgery, 27 had a mastectomy, 58 had sentinel lymph node biopsy (SLNB), and 24 had axillary dissection due to a positive SLNB or clinical axilla. Due to age and comorbidities, five patients were not suitable for axillary surgery. The median largest tumor diameter was 23 (5–100) mm. Only 23 patients (26.4%) received adjuvant chemotherapy, whereas almost all patients received hormone therapy. The median duration of follow-up was 53 (6–207) months. There was no local or systemic recurrence in any of the patients. Only 10 patients (11.5%) died from non-cancer causes during the follow-up and treatment period. In this study, tumor diameter was significantly higher in grade II/III tumors ( p = 0.039) and in patients under the age of 50 ( p = 0.027). Furthermore, lymph node metastasis was statistically significantly more likely in patients under the age of 50 (60% versus 40%, p = 0.013). Patients who had not received chemotherapy or radiotherapy tended to be older than 50 years (p = 0.002). Conclusion: In this study, the majority of patients were in the luminal subgroups with excellent prognosis and low incidences of lymph node metastasis. As a result, PMBC has favorable tumor biology. We believe that minimal axillary surgery would be the most appropriate approach during patient treatment, due to the low rate of lymph node involvement and favorable prognosis in PMBC patients.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Bitencourt AG, Graziano L, Osório CA, Guatelli CS, Souza JA, Mendonça MH, et al. MRI features of mucinous cancer of the breast: correlation with pathologic findings and other imaging methods. AJR Am J Roentgenol 2016; 206: 238-246. (PMID: 26797349) [Crossref ]
- 2. Dhillon R, Depree P, Metcalf C, Wylie E. Screen-detected mucinous breast carcinoma: potential for delayed diagnosis. Clin Radiol 2006; 61: 423-430. (PMID: 16679116) [Crossref ]
- 3. Rosen, PP. Mucinous carcinoma. In: Rosen PP (ed) Rosen’s breast pathology, 3rd edn. Lippincott-Williams and Wilkins, Philadelphia; 2009. p. 515. [Crossref ]
- 4. National Comprehensive Cancer Network: Breast cancer. In NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) (National Comprehensive Cancer Network ed., vol. 2012, v1.2012 edition. Fort Washington, PA: National Comprehensive Cancer Network; 2012. Available from URL: http://www.nccn.org/professionals/physician_gls/ pdf/breast.pdf. [Crossref ]
- 5. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinoma distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874. (PMID: 11553815) [Crossref ]
- 6. Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, et al. 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). Breast Care (Basel) 2013; 8: 221-229. (PMID: 24415975) [Crossref ]
- 7. Goodman DN, Boutross-Tadross O, Jong RA. Mammographic features of pure mucinous carcinoma of the breast with pathological correlation. Can Assoc Radiol J 1995; 46: 296-301. (PMID: 7543806) [Crossref ]
- 8. Wilson TE, Helvie MA, Oberman HA, Joynt LK. Pure and mixed mucinous carcinoma of the breast: pathologic basis for differences in mammographic appearance. AJR Am J Roentgenol 1995; 165: 285-289. (PMID: 7618541) [Crossref ]
- 9. Matsuda M, Yoshimoto M, Iwase T, Takahashi K, Kasumi F, Akiyama F, Sakamoto G. Mammographic and clinicopathological features of mucinous carcinoma of the breast. Breast Cancer 2000; 7: 65-70. (PMID: 11029773) [Crossref ]
- 10. Memis A, Ozdemir N, Parildar M, Ustun EE, Erhan Y. Mucinous (colloid) breast cancer: mammographic and US features with histologic correlation. Eur J Radiol 2000; 35: 39-43. (PMID: 10930764) [Crossref ]
- 11. Conant EF, Dillon RL, Palazzo J, Ehrlich SM, Feig SA. Imaging findings in mucin-containing carcinomas of the breast: correlation with pathologic features. AJR Am J Roentgenol 1994; 163: 821-824. (PMID: 8092016) [Crossref ]
- 12. Kawashima M, Tamaki Y, Nonaka T, Higuchi K, Kimura M, Koida T, et al. MR imaging of mucinous carcinoma of the breast. AJR Am J Roentgenol 2002; 179: 179-183. (PMID: 12076930) [Crossref ]
- 13. Okafuji T, Yabuuchi H, Sakai S, Soeda H, Matsuo Y, Inoue T, et al. MR imaging features of pure mucinous carcinoma of the breast. Eur J Radiol 2006; 60: 405-413. (PMID: 16963218) [Crossref ]
- 14. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008; 111: 541-547. (PMID: 18026874) [Crossref ]
- 15. Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg 2007; 194: 527-531. (PMID: 17826073) [Crossref ]
- 16. Toikkanen S, Kujari H. Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up. Hum Pathol 1989; 20: 758-764. (PMID: 2545592) [Crossref ]
- 17. Zhou X, Zheng Z, Li Y, Zhao W, Lin Y, Zhang J, et al. The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study. BMC Cancer 2021; 21: 536. (PMID: 33975551) [Crossref ]
- 18. Rasmussen BB, Rose C, Christensen IB. Prognostic factors in primary mucinous breast carcinoma. Am J Clin Pathol 1987; 87: 155-160. (PMID: 3028120) [Crossref ]
- 19. Komenaka IK, El-Tamer MB, Troxel A, Hamele-Bena D, Joseph KA, Horowitz E, et al. Pure mucinous carcinoma of the breast. Am J Surg 2004; 187: 528-532. (PMID: 15041505) [Crossref ]
- 20. Clayton F. Pure mucinous carcinomas of breast: morphologic features and prognostic correlates. Hum Pathol 1986; 17: 34-38. (PMID: 3002950) [Crossref ]
- 21. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10- Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017; 318: 918-926. (PMID: 28898379) [Crossref ]
- 22. Tahmasebi S, Karami M, Akrami M, Zangouri V, Asgari A, Hosseini S, et al. Clinicopathological Behavior of Mucinous Breast Carcinoma in South of Iran: The Shiraz Breast Cancer Registry. Middle East Journal of Cancer 2021; 12: 97-105. [Crossref ]
- 23. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999; 17: 1442-1448. (PMID: 10334529) [Crossref ]
- 24. Chikkannaiah P, Thangngeo D, Guruprasad C, Venkataramanappa S. Clinicopathological Study of Mucinous Carcinoma of Breast with Emphasis on Cytological Features: A Study at Tertiary Care Teaching Hospital of South India. J Lab Physicians 2020; 12: 68-75. (PMID: 32792796) [Crossref ]
- 25. Fujii H, Anbazhagan R, Bornman DM, Garrett ES, Perlman E, Gabrielson E. Mucinous cancers have fewer genomic alterations than more common classes of breast cancer. Breast Cancer Res Treat 2002; 76: 255-260. (PMID: 12462386) [Crossref ]
- 26. Yim HE, Kim JH, Ahn MS, Jung Y, Roh J, Park SH, et al. Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer. Front Oncol 2021; 10: 558760. (PMID: 33732635) [Crossref ]
- 27. Pareja F, Lee JY, Brown DN, Piscuoglio S, Gularte-Mérida R, Selenica P, et al. The Genomic Landscape of Mucinous Breast Cancer. J Natl Cancer Inst 2019; 111: 737-741. (PMID: 30649385) [Crossref ]
| APA | Emiroglu S, Tükenmez M, Karakus S, Karanlik H, Onder S, Ozmen V, Cabioglu N, Özkurt E, yilmaz r, Müslümanoğlu M (2022). Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. , 353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| Chicago | Emiroglu Selman,Tükenmez Mustafa,Karakus Seyma,Karanlik Hasan,Onder Semen,Ozmen Vahit,Cabioglu Neslihan,Özkurt Enver,yilmaz ravza,Müslümanoğlu Mahmut Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. (2022): 353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| MLA | Emiroglu Selman,Tükenmez Mustafa,Karakus Seyma,Karanlik Hasan,Onder Semen,Ozmen Vahit,Cabioglu Neslihan,Özkurt Enver,yilmaz ravza,Müslümanoğlu Mahmut Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. , 2022, ss.353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| AMA | Emiroglu S,Tükenmez M,Karakus S,Karanlik H,Onder S,Ozmen V,Cabioglu N,Özkurt E,yilmaz r,Müslümanoğlu M Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. . 2022; 353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| Vancouver | Emiroglu S,Tükenmez M,Karakus S,Karanlik H,Onder S,Ozmen V,Cabioglu N,Özkurt E,yilmaz r,Müslümanoğlu M Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. . 2022; 353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| IEEE | Emiroglu S,Tükenmez M,Karakus S,Karanlik H,Onder S,Ozmen V,Cabioglu N,Özkurt E,yilmaz r,Müslümanoğlu M "Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes." , ss.353 - 359, 2022. 10.4274/ejbh.galenos.2022.2022-8-1 |
| ISNAD | Emiroglu, Selman vd. "Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes". (2022), 353-359. https://doi.org/10.4274/ejbh.galenos.2022.2022-8-1 |
| APA | Emiroglu S, Tükenmez M, Karakus S, Karanlik H, Onder S, Ozmen V, Cabioglu N, Özkurt E, yilmaz r, Müslümanoğlu M (2022). Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. European Journal of Breast Health, 18(4), 353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| Chicago | Emiroglu Selman,Tükenmez Mustafa,Karakus Seyma,Karanlik Hasan,Onder Semen,Ozmen Vahit,Cabioglu Neslihan,Özkurt Enver,yilmaz ravza,Müslümanoğlu Mahmut Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. European Journal of Breast Health 18, no.4 (2022): 353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| MLA | Emiroglu Selman,Tükenmez Mustafa,Karakus Seyma,Karanlik Hasan,Onder Semen,Ozmen Vahit,Cabioglu Neslihan,Özkurt Enver,yilmaz ravza,Müslümanoğlu Mahmut Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. European Journal of Breast Health, vol.18, no.4, 2022, ss.353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| AMA | Emiroglu S,Tükenmez M,Karakus S,Karanlik H,Onder S,Ozmen V,Cabioglu N,Özkurt E,yilmaz r,Müslümanoğlu M Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. European Journal of Breast Health. 2022; 18(4): 353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| Vancouver | Emiroglu S,Tükenmez M,Karakus S,Karanlik H,Onder S,Ozmen V,Cabioglu N,Özkurt E,yilmaz r,Müslümanoğlu M Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. European Journal of Breast Health. 2022; 18(4): 353 - 359. 10.4274/ejbh.galenos.2022.2022-8-1 |
| IEEE | Emiroglu S,Tükenmez M,Karakus S,Karanlik H,Onder S,Ozmen V,Cabioglu N,Özkurt E,yilmaz r,Müslümanoğlu M "Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes." European Journal of Breast Health, 18, ss.353 - 359, 2022. 10.4274/ejbh.galenos.2022.2022-8-1 |
| ISNAD | Emiroglu, Selman vd. "Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes". European Journal of Breast Health 18/4 (2022), 353-359. https://doi.org/10.4274/ejbh.galenos.2022.2022-8-1 |
